417 related articles for article (PubMed ID: 30768178)
1. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
Sayed N; Ameen M; Wu JC
Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
[TBL] [Abstract][Full Text] [Related]
2. hiPSCs in cardio-oncology: deciphering the genomics.
Pinheiro EA; Fetterman KA; Burridge PW
Cardiovasc Res; 2019 Apr; 115(5):935-948. PubMed ID: 30689737
[TBL] [Abstract][Full Text] [Related]
3. Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Brown SA; Ray JC; Herrmann J
J Cardiovasc Transl Res; 2020 Jun; 13(3):402-416. PubMed ID: 32253744
[TBL] [Abstract][Full Text] [Related]
4. Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.
Pinheiro EA; Magdy T; Burridge PW
J Cardiovasc Transl Res; 2020 Jun; 13(3):377-389. PubMed ID: 32078739
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics for immunotherapy and immune-related cardiotoxicity.
Castrillon JA; Eng C; Cheng F
Hum Mol Genet; 2020 Oct; 29(R2):R186-R196. PubMed ID: 32620943
[TBL] [Abstract][Full Text] [Related]
6. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T; Burmeister BT; Burridge PW
Pharmacol Ther; 2016 Dec; 168():113-125. PubMed ID: 27609196
[TBL] [Abstract][Full Text] [Related]
7. Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer.
Kitani T; Ong SG; Lam CK; Rhee JW; Zhang JZ; Oikonomopoulos A; Ma N; Tian L; Lee J; Telli ML; Witteles RM; Sharma A; Sayed N; Wu JC
Circulation; 2019 May; 139(21):2451-2465. PubMed ID: 30866650
[TBL] [Abstract][Full Text] [Related]
8. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
Stack JP; Moslehi J; Sayed N; Wu JC
Eur Heart J; 2019 Jun; 40(22):1764-1770. PubMed ID: 29377985
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Huang MF; Pang LK; Chen YH; Zhao R; Lee DF
Cells; 2021 Oct; 10(11):. PubMed ID: 34831045
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?
Hockings JK; Castrillon JA; Cheng F
Hum Mol Genet; 2020 Oct; 29(R2):R177-R185. PubMed ID: 32601683
[TBL] [Abstract][Full Text] [Related]
11. The Role of Biomarkers in Cardio-Oncology.
Ananthan K; Lyon AR
J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
[TBL] [Abstract][Full Text] [Related]
12. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future.
Yang B; Papoian T
J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373
[TBL] [Abstract][Full Text] [Related]
13. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Perry TR; Roberts ML; Sunkara B; Maddula R; McLeish T; Gomez J; Lucas J; Rayan D; Patel S; Liang M; Bosnjak ZJ; Brown SA
Curr Oncol Rep; 2021 May; 23(7):77. PubMed ID: 33937943
[TBL] [Abstract][Full Text] [Related]
14. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
16. Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology.
Nair P; Prado M; Perea-Gil I; Karakikes I
Stem Cells Transl Med; 2019 Aug; 8(8):758-767. PubMed ID: 31020786
[TBL] [Abstract][Full Text] [Related]
17. Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.
Lam CK; Wu JC
Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):1019-1031. PubMed ID: 33472401
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.
Liu S; Fang C; Zhong C; Li J; Xiao Q
Cell Biol Toxicol; 2023 Dec; 39(6):2527-2549. PubMed ID: 37889357
[TBL] [Abstract][Full Text] [Related]
19. Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.
Magdy T; Burridge PW
Pharmacogenomics; 2021 Jan; 22(1):41-54. PubMed ID: 33448871
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy.
Feroze RA; Leya J; Herron T; Hayek SS
J Cardiovasc Transl Res; 2020 Jun; 13(3):417-430. PubMed ID: 32472498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
